Skip to search formSkip to main contentSkip to account menu

ZD-1033

Known as: ZD1033, Zeneca ZD 1033 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

anastrozole

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
A phase II study of a potent and selective aromatase inhibitor, anastrozole (ZD-1033), in Japanese postmenopausal women with advanced/recurrent breast cancer
1995
1995
104. Randomized phase III study of the new selective aromatase inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer
1995
1995
2. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer
1995
1995
351 Two randomised trials establishing efficacy and tolerability of arimidex (ZD1033) in the treatment of postmenopausal women with advanced breast cancer (PABC)
1995
1995
356 A randomised, double-blind, multicentre crossover trial to evaluate in-vivo inhibition of aromatase by arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer
Review
1993
Review
1993
[Recent development of endocrine treatment for breast cancer--new drugs and new treatment methods using tamoxifen].
The characteristics and clinical efficacies of new hormonal drugs and new treatment methods for breast cancer using tamoxifen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)